Methods of treating prostate cancer with GnRH antagonist

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10729739
APP PUB NO 20170290879A1
SERIAL NO

15405552

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
FERRING B V2132 JX HOOFDDORP

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cantor, Per Charlottenlund, DK 8 50
Jensen, Jens-Kristian Slott Bagsvaerd, DK 7 25
Olesen, Tine Kold New York, US 8 50
Persson, Bo-Eric St. Prex, CH 14 60
van, der Meulen Egbert A Dalby, SE 11 46

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 4, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 4, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00